
TB remains the bacterial pathogen responsible for the greatest burden of disease, causing well over a million deaths every year. Control of TB has been set back markedly by the COVID-19 pandemic, and drug resistance is a growing global challenge. Methods of timely diagnosis and shorter treatment regimens remain key goals for clinical TB research, alongside the development of vaccines to prevent TB infection and progression to active disease.

Diagnostics
4 grants
€51.19 M

Vaccines
19 grants
€76.88 M

Drugs
10 grants
€66.76 M

33 grants
€194.83 M

Accelerating TB vaccine development


Preventing latent TB progression


An alternative to BCG for prevention of TB infection


Advancing TB drug development


Statins for TB


A new approach for treatment of TB-related meningitis


Optimising molecular testing for TB


‘Universal’ screening for HIV and TB


Seeking out TB cases


More efficient detection of TB


An alternative to BCG for newborns

